Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod

Abstract

Background:

Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS).

Objective:

To determine the correlation of NFL in CSF and serum/plasma, and in plasma after switching from injectable MS therapies to fingolimod.

Methods:

A first cohort consisted of MS patients (n = 39) and neurological disease controls (n = 27) where CSF and plasma/serum had been collected for diagnostic purposes. A second cohort (n = 243) consisted of patients from a post-marketing study of fingolimod. NFL was determined with Single Molecule Array (Simoa™) technology (detection threshold 1.95 pg/mL).

Results:

Mean NFL pg/mL (standard deviation (SD)) was 341 (267) and 1475 (2358) in CSF and 8.2 (3.58) and 17.0 (16.94) in serum from controls and MS, respectively. CSF/serum and plasma/serum levels were highly correlated (n = 66, rho = 0.672, p < 0.0001 and n = 16, rho = 0.684, p = 0.009, respectively). In patients starting fingolimod (n = 243), mean NFL pg/mL (SD) in plasma was reduced between baseline (20.4 (10.7)) and at 12 months (13.5 (7.3), p < 3 × 10⁻⁶), and levels remained stable at 24 months (13.2 (6.2)).

Conclusion:

NFL in serum and CSF are highly correlated and plasma NFL levels decrease after switching to highly effective MS therapy. Blood NFL measurement can be considered as a biomarker for MS therapy response.

Keywords

Multiple sclerosis drug response biomarkers beta-interferon glatiramer acetate fingolimod neurofilament

Get full access to this article

View all access options for this article.

References

Sormani

Bruzzi

MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013; 12: 669–676.

Tallantyre

Al-Rawashdeh

. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler 2010; 16: 406–411.

Wattjes

Rovira

Miller

. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015; 11: 597–606.

Comabella

Montalban

Body fluid biomarkers in multiple sclerosis. Lancet Neurol 2014; 13: 113–126.

Kuhle

Malmestrom

Axelsson

. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: e33–e36.

Kuhle

Plattner

Bestwick

. A comparative study of CSF neurofilament light and heavy chain protein in MS. Mult Scler 2013; 19: 1597–1603.

Teunissen

Khalil

Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552–556.

Kuhle

Disanto

Lorscheider

. Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Neurology 2015; 84: 1639–1643.

Romme Christensen

Ratzer

Bornsen

. Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial. Neurology 2014; 82: 1499–1507.

10.

Gnanapavan

Grant

Morant

. Biomarker report from the phase II lamotrigine trial in secondary progressive MS—Neurofilament as a surrogate of disease progression. PLoS ONE 2013; 8: e70019.

11.

Axelsson

Malmestrom

Gunnarsson

. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43–50.

12.

Gunnarsson

Malmestrom

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.

13.

Novakova

Axelsson

Khademi

. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. J Neurochem 2017; 141: 296–304.

14.

Khademi

Dring

Gilthorpe

. Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: A reflection by cerebrospinal fluid biomarkers. PLoS ONE 2013; 8: e63172.

15.

Disanto

Adiutori

Dobson

. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J Neurol Neurosurg Psychiatry 2016; 87: 126–129.

16.

Kuhle

Barro

Disanto

. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler 2016; 22: 1550–1559.

17.

Kuhle

Nourbakhsh

Grant

. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 2017; 88: 826–831.

18.

Gaiottino

Norgren

Dobson

. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013; 8: e75091.

19.

Gisslen

Price

Andreasson

. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study. EBioMedicine 2016; 3: 135–140.

20.

Kuhle

Barro

Andreasson

. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 2016; 54: 1655–1661.

21.

Trapp

Peterson

Ransohoff

. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278–285.

22.

Calabrese

Magliozzi

Ciccarelli

. Exploring the origins of grey matter damage in multiple sclerosis. Nat Rev Neurosci 2015; 16: 147–158.

23.

Bacioglu

Maia

Preische

. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 2016; 91: 56–66.

24.

Hansson

Janelidze

Hall

. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology 2017; 88: 930–937.

25.

Rojas

Karydas

Bang

. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016; 3: 216–225.

26.

Rohrer

Woollacott

Dick

. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 2016; 87: 1329–1336.

27.

Zetterberg

Skillback

Mattsson

. Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol 2016; 73: 60–67.

28.

Shahim

Gren

Liman

. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep 2016; 6: 36791.

29.

Ontaneda

Fox

RJ.

Imaging as an outcome measure in multiple sclerosis. Neurotherapeutics 2017; 14: 24–34.

30.

Vagberg

Norgren

Dring

. Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS ONE 2015; 10: e0135886.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB